Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.200 +0.110 (+10.09%)
Streaming Delayed Price Updated: 2:38 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,309,161
Open 1.200
Bid (Size) 1.200 (89)
Ask (Size) 1.210 (14)
Prev. Close 1.090
Today's Range 1.130 - 1.250
52wk Range 0.5600 - 1.930
Shares Outstanding 44,105,078
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga

Performance

YTD
+57.40%
+57.40%
1 Month
+69.01%
+69.01%
3 Month
-15.49%
-15.49%
6 Month
+42.84%
+42.84%
1 Year
+20.00%
+20.00%

More News

Read More
Dow Tumbles 100 Points; Micron Technology Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
Via Benzinga
Recap: Avrobio Q1 Earnings
Via Benzinga
Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higher
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
From AVROBIO, Inc.
Via Business Wire
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months
Via Benzinga
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Leadership Transition
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.